Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years

Details

Serval ID
serval:BIB_23B72C29CB27
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years
Journal
Journal of Endocrinological Investigation
Author(s)
Lamy  O., Sandini  L., Pache  I., Fatio  S., Burnand  J., Burckhardt  P.
ISSN
0391-4097 (Print)
Publication state
Published
Issued date
08/2003
Volume
26
Number
8
Pages
728-32
Notes
Clinical Trial
Journal Article --- Old month value: Aug
Abstract
In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg ibandronate injected every 3 months was tested in men with osteoporosis over 2 yr, in a prospective, open study. Fourteen men with primary osteoporosis, mean age 57 +/- 12 yr (range: 40-73), received 2-mg ibandronate iv every 3 months over 2 yr. All got 1 g/day calcium and 880 UI/day vitamin D for 2 yr. Bone mineral density (BMD) increased after 2 yr by 6.7 +/- 1.5% (mean change +/- SEM) at lumbar spine (p<0.001), by 3.2 +/- 08% at trochanter (p<0.001) and by 1.4 +/- 1.1% at femoral neck (ns). Serum beta-crosslaps and osteocalcin decreased significantly by 30-45 and 30%, respectively, during the 2 yr of treatment. Serum calcium increased from the lower to the middle tertile of the normal range during the 2 yr of the study. The observed decrease of bone remodelling and the increase of BMD are of the same magnitude as those described with oral bisphosphonates. The increase of plasma calcium confirms the positive effect of the supplementation with calcium and vitamin D. These results suggest that 3 months are a good interval between two doses of iv ibandronate, when 2 mg are given.
Keywords
Adult Aged Aged, 80 and over Biological Markers Bone Density/drug effects Bone and Bones/metabolism Diphosphonates/administration & dosage/adverse effects/*therapeutic use Follow-Up Studies Fractures, Bone/epidemiology Humans Injections, Intravenous Male Middle Aged Osteoporosis/*drug therapy/pathology Pilot Projects Spine/anatomy & histology/pathology
Pubmed
Web of science
Create date
25/01/2008 13:55
Last modification date
20/08/2019 13:01
Usage data